SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Dainippon Sumitomo Pharma Co., Ltd. and Intercept Pharmaceuticals Announce Agreement to Develop and Commercialize Obeticholic Acid (INT-747) for Chronic Liver Disease; Dainippon Pays Intercept $15 Million and up to $300 Million